Investor Presentation First Nine Months of 2023

100 Investor presentation First nine months of 2023 MASH is a progressive disease with no approved treatment and low diagnosis rates today MASH-Cirrhosis F4 MASH F3 MASH F2 MASH F1 Inflamed tissue Large lipid droplets Inflamed/dying hepatocyte Collagen fibres Inflamed/dying hepatocyte Excessive collagen deposition Dead cell remnants Scar tissue Diagnosis rates Treatment rates Source: Novo Nordisk estimates MASH: Metabolic dysfunction-associated steatohepatitis Note: MASH was formerly known as NASH (Nonalcoholic steatohepatitis) 26% 32% 42% 50% 70% 90% Novo NordiskⓇ

View entire presentation